Other Studies Indicating that Clarithromycin is a Good Option for Covid-19:
Another exciting study made in Iran, experienced docking experiments using the newly released coordinate structure for COVID-19 protease as a receptor and nine drugs were selected from HIV-1 protease inhibitors and twenty-one candidates from anti bronchitis drugs, based on their chemical structures and enrolled them in blind and active site-directed dockings in different modes and native-like conditions of interactions. These experiments suggested that the binding capacity and the inhibitory potency of those candidates were as follows: Tipranavir >Indinavir>Atazanavir>Darunavir>Ritonavir>Amprenavir for HIV-1, and Cefditoren>Cefixime>Erythromycin>Clarithromycin for anti-bronchitis medicines (82). In this context the author imagines that a successful treatment regime should contain multi drugs of protease inhibitors, spike shielding drugs, and immunomodulatory drugs in early steps of the disease and Ivermectin>heparin (as intravenous or nebulized)>macrolides seemed to them to be good adjuvant candidates in all anti 2019-nCov regimes to shield S protein even for prophylactic purposes (83).
Other small experiences appeared in the scientific literature later on in a similar direction. One study in Taiwan, reported two cases with community-acquired pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who returned from Wuhan, China. In hospital, one patient positive for the virus remained febrile, malaise and poor appetite. Follow-up CXR revealed increasing opacity at right middle and lower lung fields. Levofloxacin was initiated. On hospital day 12, after a 6-day course of Levofloxacin, her fever abated with improved appetite and physical activity. She became free of symptoms afterward. The second patient on day 6 in hospital, remained febrile, malaise and poor appetite. She reported worsening of cough. Follow-up CXR revealed patchy consolidation over bilateral lower lung field. Parenteral Cefepime and oral Clarithromycin therapy were initiated. On day 9, she was afebrile with improved general condition. Antimicrobial therapy was shifted to oral Moxifloxacin. She remained free of symptoms afterward (84).
In Colombia, as published, one patient received clarithromycin instead of azithromycin, in combination with chloroquine with the successful recovery of COVID‐19 pneumonia, without any side adverse effects and become negative for the SARS-CoV-2 infection, as observed in the RT-PCR test. (85).
In Ecuador 12 patients were treated with a combination of Clarithromycin, N-acetilcystine and an antiviral nutraceutical (Virusid) with excellent outcomes (86).
Clarithromycin should be the best candidate to be tried for COVID-19 from all this evidence is obvious for us.